Radiopharm Theranostics Ltd Ordinary Shares RDPTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.00–0.01
- 52-Week Range
- $0.00–0.02
- Bid/Ask
- $0.00 / $1.00
- Shares Outstanding
- 4.38B
- Market Cap
- $15.76M
- Volume/Avg
- 12,000 / 11,000
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. It develops and commercializes radiopharmaceutical platforms for therapeutic and diagnostic applications in precision oncology. The Company develops targeted and scientifically validated radiopharmaceutical technologies in pre-clinical and clinical stages. It has one reportable segment, being the research, development, and commercialization of health technologies. The Company operates in Australia and the United States, with maximum revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
Valuation
|
Metric
|
RDPTF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.39 |
Price/Sales | 10.92 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RDPTF
|
|---|---|
Quick Ratio | 1.14 |
Current Ratio | 1.16 |
Interest Coverage | −510.88 |
Quick Ratio
RDPTF
Profitability
|
Metric
|
RDPTF
|
|---|---|
Return on Assets (Normalized) | −76.78% |
Return on Equity (Normalized) | −162.03% |
Return on Invested Capital (Normalized) | −92.07% |
Return on Assets
RDPTF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<<!^%h@ | LOCK|!xY!q | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!JNvd%$ | LOCK|L%!& | $83B | |||
| Moderna Inc
MRNA
| LOCK|%dJc%fd | LOCK|#@m | $80B | |||
| argenx SE ADR
ARGX
| LOCK|LjK@G&R | LOCK|&mv | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|NXrwyy> | LOCK|$DB | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|k!%JhNK | LOCK|%X#F# | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|QL$G<$vm | LOCK|Yt<< | $28B | |||
| Incyte Corp
INCY
| LOCK|QXS?Vd | LOCK|vz | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|WX^FHFY | LOCK|Wx | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|cfv?%m | LOCK|P&> | $14B |
United States